MIME-Version: 1.0
Content-Type: multipart/related; boundary="----=_NextPart_01D8F861.E5FBF300"

Данный документ является веб-страницей в одном файле, также называемой файлом веб-архива. Если вы видите это сообщение, значит, данный браузер или редактор не поддерживает файлы веб-архива. Загрузите браузер, поддерживающий веб-архивы, например Windows® Internet Explorer®.

------=_NextPart_01D8F861.E5FBF300
Content-Location: file:///C:/6811EA75/UA06870101_B925.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1251"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns:st1=3D"urn:schemas-microsoft-com:office:smarttags"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
1">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 14">
<meta name=3DOriginator content=3D"Microsoft Word 14">
<link rel=3DFile-List href=3D"UA06870101_B925.files/filelist.xml">
<link rel=3DPreview href=3D"UA06870101_B925.files/preview.wmf">
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"metricconverter"/>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Шумна Ірина Миколаївна</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>Bravada</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>4</o:TotalTime>
  <o:LastPrinted>2022-10-11T14:39:00Z</o:LastPrinted>
  <o:Created>2022-11-14T17:47:00Z</o:Created>
  <o:LastSaved>2022-11-14T17:47:00Z</o:LastSaved>
  <o:Pages>4</o:Pages>
  <o:Words>1571</o:Words>
  <o:Characters>8958</o:Characters>
  <o:Company>Державний експертний центр</o:Company>
  <o:Lines>74</o:Lines>
  <o:Paragraphs>21</o:Paragraphs>
  <o:CharactersWithSpaces>10508</o:CharactersWithSpaces>
  <o:Version>14.00</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=3DdataStoreItem href=3D"UA06870101_B925.files/item0001.xml"
target=3D"UA06870101_B925.files/props002.xml">
<link rel=3DthemeData href=3D"UA06870101_B925.files/themedata.thmx">
<link rel=3DcolorSchemeMapping href=3D"UA06870101_B925.files/colorschememap=
ping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:HyphenationZone>21</w:HyphenationZone>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>RU</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:DontUseIndentAsNumberingTabStop/>
   <w:FELineBreak11/>
   <w:WW11IndentRules/>
   <w:DontAutofitConstrainedTables/>
   <w:AutofitLikeWW11/>
   <w:HangulWidthLikeWW11/>
   <w:UseNormalStyleForList/>
   <w:DontVertAlignCellWithSp/>
   <w:DontBreakConstrainedForcedTables/>
   <w:DontVertAlignInTxbx/>
   <w:Word11KerningPairs/>
   <w:CachedColBalance/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val=3D"Cambria Math"/>
   <m:brkBin m:val=3D"before"/>
   <m:brkBinSub m:val=3D"&#45;-"/>
   <m:smallFrac/>
   <m:dispDef/>
   <m:lMargin m:val=3D"0"/>
   <m:rMargin m:val=3D"0"/>
   <m:defJc m:val=3D"centerGroup"/>
   <m:wrapIndent m:val=3D"1440"/>
   <m:intLim m:val=3D"subSup"/>
   <m:naryLim m:val=3D"undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState=3D"false" DefUnhideWhenUsed=3D"true"
  DefSemiHidden=3D"true" DefQFormat=3D"false" DefPriority=3D"99"
  LatentStyleCount=3D"267">
  <w:LsdException Locked=3D"false" Priority=3D"0" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Normal"/>
  <w:LsdException Locked=3D"false" Priority=3D"0" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"heading 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"0" QFormat=3D"true" Name=3D"=
heading 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 7"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 8"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 9"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 7"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 8"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 9"/>
  <w:LsdException Locked=3D"false" Priority=3D"0" Name=3D"footer"/>
  <w:LsdException Locked=3D"false" Priority=3D"35" QFormat=3D"true" Name=3D=
"caption"/>
  <w:LsdException Locked=3D"false" Priority=3D"0" Name=3D"page number"/>
  <w:LsdException Locked=3D"false" Priority=3D"10" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" Name=3D"Default Paragraph=
 Font"/>
  <w:LsdException Locked=3D"false" Priority=3D"0" Name=3D"Body Text"/>
  <w:LsdException Locked=3D"false" Priority=3D"11" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtitle"/>
  <w:LsdException Locked=3D"false" Priority=3D"22" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Strong"/>
  <w:LsdException Locked=3D"false" Priority=3D"20" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"0" Name=3D"Normal (Web)"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Table Grid"/>
  <w:LsdException Locked=3D"false" UnhideWhenUsed=3D"false" Name=3D"Placeho=
lder Text"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"No Spacing"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" UnhideWhenUsed=3D"false" Name=3D"Revisio=
n"/>
  <w:LsdException Locked=3D"false" Priority=3D"34" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"List Paragraph"/>
  <w:LsdException Locked=3D"false" Priority=3D"29" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"30" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"19" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtle Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"21" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"31" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtle Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"32" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"33" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Book Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"37" Name=3D"Bibliography"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" QFormat=3D"true" Name=3D=
"TOC Heading"/>
 </w:LatentStyles>
</xml><![endif]--><!--[if !mso]><object
 classid=3D"clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=3Dieooui></objec=
t>
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:204;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520092929 1073786111 9 0 415 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:204;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520081665 -1073717157 41 0 66047 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Заголовок 1 Знак";
	mso-style-next:Обычный;
	margin:0cm;
	margin-bottom:.0001pt;
	text-align:right;
	mso-pagination:none;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-font-kerning:0pt;
	font-weight:normal;}
h3
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Заголовок 3 Знак";
	mso-style-next:Обычный;
	margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:none;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:14.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	font-weight:normal;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-unhide:no;
	mso-style-link:"Нижний колонтитул Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:none;
	tab-stops:center 207.65pt right 415.3pt;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-unhide:no;
	mso-style-link:"Основной текст Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:UK;}
p
	{mso-style-unhide:no;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Текст выноски Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:8.0pt;
	font-family:"Tahoma","sans-serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParag=
raphCxSpFirst
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListPar=
agraphCxSpMiddle
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagra=
phCxSpLast
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
span.1
	{mso-style-name:"Заголовок 1 Знак";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Заголовок 1";
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:RU;
	mso-fareast-language:RU;}
span.3
	{mso-style-name:"Заголовок 3 Знак";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Заголовок 3";
	mso-ansi-font-size:14.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:RU;
	mso-fareast-language:RU;}
span.a
	{mso-style-name:"Нижний колонтитул Знак";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Нижний колонтитул";
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:RU;
	mso-fareast-language:RU;}
span.10
	{mso-style-name:"Основной текст + Полужирный1";
	mso-style-unhide:no;
	mso-style-parent:"";
	mso-ansi-font-size:11.5pt;
	mso-bidi-font-size:11.5pt;
	mso-bidi-language:AR-SA;
	font-weight:bold;}
p.11, li.11, div.11
	{mso-style-name:"заголовок 1";
	mso-style-unhide:no;
	mso-style-next:Обычный;
	margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	text-autospace:none;
	font-size:14.0pt;
	font-family:"Arial","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
span.a0
	{mso-style-name:"Основной текст Знак";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Основной текст";
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:RU;}
span.a1
	{mso-style-name:"Текст выноски Знак";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Текст выноски";
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;
	font-family:"Tahoma","sans-serif";
	mso-ascii-font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:Tahoma;
	mso-bidi-font-family:Tahoma;
	mso-ansi-language:RU;
	mso-fareast-language:RU;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	mso-ascii-font-family:Calibri;
	mso-fareast-font-family:Calibri;
	mso-hansi-font-family:Calibri;}
 /* Page Definitions */
 @page
	{mso-footnote-separator:url("UA06870101_B925.files/header.htm") fs;
	mso-footnote-continuation-separator:url("UA06870101_B925.files/header.htm"=
) fcs;
	mso-endnote-separator:url("UA06870101_B925.files/header.htm") es;
	mso-endnote-continuation-separator:url("UA06870101_B925.files/header.htm")=
 ecs;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:42.55pt 35.35pt 2.0cm 2.0cm;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-even-footer:url("UA06870101_B925.files/header.htm") ef1;
	mso-footer:url("UA06870101_B925.files/header.htm") f1;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 @list l0
	{mso-list-id:1288045959;
	mso-list-type:hybrid;
	mso-list-template-ids:-1428791040 1459535960 69337091 69337093 69337089 69=
337091 69337093 69337089 69337091 69337093;}
@list l0:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:18.0pt;
	text-indent:-18.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-font-style:italic;}
@list l0:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:54.0pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l0:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:90.0pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l0:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:126.0pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l0:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:162.0pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l0:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:198.0pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l0:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:234.0pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l0:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:270.0pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l0:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:306.0pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1
	{mso-list-id:1511988301;
	mso-list-type:hybrid;
	mso-list-template-ids:-549971172 -546817816 69337091 69337093 69337089 693=
37091 69337093 69337089 69337091 69337093;}
@list l1:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:\F02D;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:18.0pt;
	text-indent:-18.0pt;
	font-family:Symbol;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
@list l1:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:54.0pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:90.0pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:126.0pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l1:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:162.0pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:198.0pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:234.0pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l1:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:270.0pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:306.0pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l2
	{mso-list-id:1793018317;
	mso-list-type:hybrid;
	mso-list-template-ids:-496480854 -546817816 69337091 69337093 69337089 693=
37091 69337093 69337089 69337091 69337093;}
@list l2:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:\F02D;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
@list l2:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l2:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l2:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l2:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l2:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l2:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l2:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l2:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Обычная таблица";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext=3D"edit">
  <o:idmap v:ext=3D"edit" data=3D"1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=3DRU style=3D'tab-interval:35.4pt'>

<div class=3DWordSection1>

<h3 style=3D'margin-left:14.2pt;text-indent:-14.2pt;mso-pagination:widow-or=
phan'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'font-size:12=
.0pt;
mso-ansi-language:UK'>ІНСТРУКЦІЯ<o:p></o:p></span></b></h3>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><b style=3D=
'mso-bidi-font-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>для
медичного застосування лікарського засобу <o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><b style=3D=
'mso-bidi-font-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'><o:=
p>&nbsp;</o:p></span></b></p>

<p class=3D11 style=3D'mso-pagination:none;mso-layout-grid-align:none'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
text-transform:uppercase;mso-ansi-language:UK'>Біоарон </span><span lang=3D=
UK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-la=
nguage:
UK'>CИСТЕМ<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'><o:=
p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;mso-ansi-language:UK'>Склад: <o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i><span lang=3DUK
style=3D'font-size:12.0pt;mso-ansi-language:UK;mso-bidi-font-weight:bold'>д=
іючі
речовини: </span></i><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-lan=
guage:
UK'>100 мл препарату містять екстракту алое рідкого <i style=3D'mso-bidi-fo=
nt-style:
normal'>(Aloe arborescens)</i> (1:4) 38,4 г (екстрагент: вода очищена),
вітаміну C <st1:metricconverter ProductID=3D"1,02 г" w:st=3D"on">1,02 г</st=
1:metricconverter>;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>доп=
оміжні
речовини: </span></i><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-lan=
guage:
UK'>сахароза, сік аронії концентрований <i style=3D'mso-bidi-font-style:nor=
mal'>(Aronia
melanocarpa)</i>, натрію бензоат, вода очищена.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'><o:=
p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>Лік=
арська
форма. </span></b><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-langua=
ge:UK'>Сироп.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;mso-layout-grid-align:none;
text-autospace:none'><i><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-=
language:
UK'>Основні фізико-хімічні властивості:</span></i><span lang=3DUK
style=3D'font-size:12.0pt;mso-ansi-language:UK;mso-bidi-font-weight:bold;
mso-bidi-font-style:italic'> р</span><span lang=3DUK style=3D'font-size:12.=
0pt;
mso-ansi-language:UK'>ідина червоно-коричневого кольору з характерним запах=
ом.
У процесі зберігання може утворюватися осад<i style=3D'mso-bidi-font-style:=
normal'>.<o:p></o:p></i></span></p>

<p class=3DMsoNormal><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-lan=
guage:
UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>Фар=
макотерапевтична
група. </span></b><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-langua=
ge:UK'>Тонізуючі
засоби. <span style=3D'mso-bidi-font-weight:bold'>Код ATХ </span>А13А.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;mso-ansi-language:UK'>Фармакологічні властивості.<o:p></o:p></span><=
/i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>Фар=
макодинаміка<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-fareast-font-family:Calibri;mso-ansi-language:UK'>Механізм дії до
кінця не вивчений і базується виключно на результатах доклінічний досліджен=
ь.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-fareast-font-family:Calibri;mso-ansi-language:UK'>Передбачуваний
механізм дії заснований насамперед на активації клітин імунної системи </sp=
an><span
lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>–</span><span lan=
g=3DUK
style=3D'font-size:12.0pt;mso-fareast-font-family:Calibri;mso-ansi-language=
:UK'>
В- і Т-лімфоцитів, нейтрофілів, макрофагів, С-3 компонента комплементу. З
огляду на бібліографічні дані передбачається, що за імунологічну дію значною
мірою відповідають глікопротеїни (лектини S-1 та P-2) та полісахариди (пере=
важно
ацеманан).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-fareast-font-family:Calibri;mso-ansi-language:UK'>Фармакодинаміч=
ні
властивості ґрунтуються на тваринних моделях та культурах клітин тварин і
людини. Клінічні фармакологічні дослідження не проводились.<o:p></o:p></spa=
n></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-fareast-font-family:Calibri;mso-ansi-language:UK'>В дослідженнях
імунологічної активності <i style=3D'mso-bidi-font-style:normal'>in vivo</i=
> а
також <i style=3D'mso-bidi-font-style:normal'>ex vivo/in vitro </i>Біоарон =
СИСТЕМ
показав імуномодулюючу дію, тобто виявляв стимулюючу дію як на гуморальну
реакцію, так і на клітинну: спостерігалися ріст неспецифічної клітинної
відповіді та початкової гуморальної реакції, стимуляція вироблення антитіл,
стимуляція хемокінетичної активності клітин, стимуляція фагоцитозу
нейтрофілами, стимуляція проліферації В- і Т-лімфоцитів (безвідносно до міт=
огену).
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-fareast-font-family:Calibri;mso-ansi-language:UK'>Також
спостерігалося зниження бронхіальної реактивності на гістамін під впливом
діючої речовини екстракту алое рiдкого (<i style=3D'mso-bidi-font-style:nor=
mal'>Aloe
arborescens</i>).<i style=3D'mso-bidi-font-style:normal'><o:p></o:p></i></s=
pan></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-fareast-font-family:Calibri;mso-ansi-language:UK'>В дослідах <i
style=3D'mso-bidi-font-style:normal'>in vitro</i> препарат пригнічував запа=
льні
реакції, продукування та вивільнення маркерів запалення IL-6, TNF-&#945;, і
LB-1&#946;, гістаміну, брадикініну, а також ейкозаноїдів.<o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-fareast-font-family:Calibri;mso-ansi-language:UK'>Біоарон СИСТЕМ=
 в
умовах <i style=3D'mso-bidi-font-style:normal'>in vitro </i>суттєво пригніч=
ує
ріст РНК-вірусів, зокрема: вірусу грипу A (HINI та H3N2), вірусу грипу B
(Yamagatal та Beiying), риновірусу (HRV 14) та вірусу Коксакі (CA9). Слабо
виражена пригнічувальна дія на респіраторно-синцитіальний вірус (RSV) та ві=
рус
парагрипу (Para 3). Відсутня пригнічувальна дія на ДНК-вірус аденовірус (Ad=
eno
5).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-fareast-font-family:Calibri;mso-ansi-language:UK'>Біоарон СИСТЕМ
виявляв протимікробну активність в умовах <i style=3D'mso-bidi-font-style:n=
ormal'>in
vitro</i> щодо бактерій, зокрема <i style=3D'mso-bidi-font-style:normal'>St=
aphylococcus
aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus ang=
inosus,
Klebsiella pneumoniae, Haemophilus influenzae, Moraxella catarrhalis,
Pseudomonasaeruginosa,</i> та дріжджових грибків <i style=3D'mso-bidi-font-=
style:
normal'>Candida albicans.</i><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-fareast-font-family:C=
alibri;
mso-ansi-language:UK'>Лікування інфекцій верхніх дихальних шляхів<o:p></o:p=
></span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-fareast-font-family:Calibri;mso-ansi-language:UK'>У неінтервенці=
йних
обсерваційних дослідженнях та в одному рандомізованому клінічному досліджен=
ні застосування
лікарського засобу Біоарон СИСТЕМ призвело до нормалізації субпопуляції Т-л=
імфоцитів
та рівня прозапальних цитокінів у дітей з інфекціями дихальних шляхів порів=
няно
з контрольною групою. В результаті прийому препарату імунна відповідь була
відновлена &#8203;&#8203;до норми (імуномодулюючий ефект). Крім того,
тривалість інфекційного захворювання була меншою і його перебіг був легшим:
менша вираженість симптомів, пов’язаних із запальною реакцією, таких як неж=
ить,
підвищена температура тіла та кашель. Виражене покращення клінічного стану
спостерігалось приблизно у 60 % дітей, тоді як у контрольній групі </span><=
span
lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>–</span><span lan=
g=3DUK
style=3D'font-size:12.0pt;mso-fareast-font-family:Calibri;mso-ansi-language=
:UK'>
приблизно у 40 % дітей.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-fareast-font-family:C=
alibri;
mso-ansi-language:UK'>Профілактика інфекцій верхніх дихальних шляхів<o:p></=
o:p></span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-fareast-font-family:Calibri;mso-ansi-language:UK'>Профілактичне
застосування лікарського засобу Біоарон СИСТЕМ у дітей з рецидивуючими
інфекціями, такими як риніт, назофарингіт, гострий бронхіт, у порівнянні з
дітьми контрольної групи зменшує частоту рецидивів, подовжує період ремісії=
 та
збільшує стійкість до повторного інфікування у 2,6 раза.<o:p></o:p></span><=
/p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-fareast-font-family:C=
alibri;
mso-ansi-language:UK'>Відсутність апетиту<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-fareast-font-family:Calibri;mso-ansi-language:UK'>Дослідження
показали збільшення апетиту у 47</span><span lang=3DUK style=3D'font-size:1=
2.0pt;
mso-ansi-language:UK'>–</span><span lang=3DUK style=3D'font-size:12.0pt;mso=
-fareast-font-family:
Calibri;mso-ansi-language:UK'>65 % дітей, які отримували Біоарон СИСТЕМ під=
 час
лікування інфекцій дихальних шляхів.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-fareast-font-family:C=
alibri;
mso-ansi-language:UK'>Педіатрична популяція (діти та підлітки)<o:p></o:p></=
span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-fareast-font-family:Calibri;mso-ansi-language:UK'>Дослідження
лікарського засобу Біоарон СИСТЕМ проводились переважно за участю <span
style=3D'mso-spacerun:yes'> </span>педіатричних пацієнтів (діти віком 3</sp=
an><span
lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>–</span><span lan=
g=3DUK
style=3D'font-size:12.0pt;mso-fareast-font-family:Calibri;mso-ansi-language=
:UK'>16
років).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>Клі=
нічні
характеристики.<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;mso-ansi-language:UK'>Показання.<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-fareast-font-family:Calibri;mso-ansi-language:UK'>Біоарон СИСТЕМ=
 </span><span
lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>застосовують:<o:p=
></o:p></span></p>

<p class=3DMsoListParagraphCxSpFirst style=3D'margin-left:14.2pt;mso-add-sp=
ace:
auto;text-align:justify;text-indent:-14.2pt;mso-list:l2 level1 lfo3'><![if =
!supportLists]><span
lang=3DUK style=3D'font-size:12.0pt;font-family:Symbol;mso-fareast-font-fam=
ily:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:UK'><span
style=3D'mso-list:Ignore'>-<span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
mso-ansi-language:UK'>як допоміжний засіб при інфекціях верхніх дихальних
шляхів, у т. ч. для лікування застуди; <o:p></o:p></span></p>

<p class=3DMsoListParagraphCxSpMiddle style=3D'margin-left:14.2pt;mso-add-s=
pace:
auto;text-align:justify;text-indent:-14.2pt;mso-list:l2 level1 lfo3'><![if =
!supportLists]><span
lang=3DUK style=3D'font-size:12.0pt;font-family:Symbol;mso-fareast-font-fam=
ily:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:UK'><span
style=3D'mso-list:Ignore'>-<span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
mso-ansi-language:UK'>при відсутності апетиту.<o:p></o:p></span></p>

<p class=3DMsoListParagraphCxSpLast style=3D'margin-left:14.2pt;mso-add-spa=
ce:auto;
text-align:justify'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-lang=
uage:
UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;mso-ansi-language:UK'>Протипоказання.</span></i></b><i style=3D'mso-=
bidi-font-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'><o:=
p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Абсолютні протипоказання:<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><span style=3D'mso-spacerun:yes'> </span>- під=
вищена
чутливість до активних речовин або до будь-якої з допоміжних речовин,
зазначених у розділі «Склад»;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><span style=3D'mso-spacerun:yes'> </span>- одн=
очасне
застосування імунодепресивних препаратів.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Відносні протипоказання:<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><span style=3D'mso-spacerun:yes'> </span>-
схильність до алергії;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><span style=3D'mso-spacerun:yes'> </span>- сис=
темні
захворювання та аутоімунні захворювання (наприклад системна склеродермія,
системний вовчак, хвороба Хашимото, хвороба Грейвса, Базедова хвороба,
розсіяний склероз, інсулінозалежний діабет, ревматоїдний артрит);<o:p></o:p=
></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><span style=3D'mso-spacerun:yes'> </span>-
підвищений рівень імуноглобулінів у крові.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>У разі вищезазначених відносних протипоказань =
рішення
про застосування препарату приймає лікар на основі клінічної картини та з
урахуванням ефективності препарату і співвідношення користь/ризик.<o:p></o:=
p></span></p>

<p class=3DMsoNormal><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-lan=
guage:
UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><i style=3D'm=
so-bidi-font-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>Вза=
ємодія з
іншими лікарськими засобами та інші види взаємодій.</span></i></b><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
mso-ansi-language:UK'><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:i=
talic'>Взаємодії
сиропу Біоарон СИСТЕМ з іншими лікарськими засобами або іншими речовинами
невідомі. В ході досліджень Біоарон СИСТЕМ застосовувався разом з іншими
стандартними лікарськими засобами для лікування респіраторних інфекцій,
антибіотиками; про лікарські взаємодії не повідомлялося. Також в процесі
фармаконагляду не отримано жодних сигналів щодо потенційних взаємодій
лікарських засобів.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:i=
talic'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:i=
talic'>Одна
доза сиропу Біоарон СИСТЕМ для всіх вікових груп містить 51 мг вітаміну С, в
максимальній добовій дозі препарату (15 мл) вміст вітаміну С становить 153 =
мг.
Взаємодія та побічні реакції, пов’язані із застосуванням високих доз вітамі=
ну
С, не поширюються на застосування вітаміну С у складі лікарського засобу
Біоарон СИСТЕМ.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'><o:=
p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span class=3D10><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
mso-ansi-language:UK'>Особливості застосування.</span></i></span><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
mso-ansi-language:UK'><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><u><span lang=3DUK
style=3D'font-size:12.0pt;mso-ansi-language:UK'>Застосування лікарського за=
собу
Біоарон СИСТЕМ хворим на цукровий діабет<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Разова доза препарату (5 мл) містить приблизно
3,93 г сахарози. Застосовувати з обережністю пацієнтам із цукровим діабетом=
.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><u><span lang=3DUK
style=3D'font-size:12.0pt;mso-ansi-language:UK'>Пацієнтам з рідкісною
непереносимістю фруктози, мальабсорбцією глюкози-галактози або дефіцитом
сахарази-ізомальтази</span></u><span lang=3DUK style=3D'font-size:12.0pt;
mso-ansi-language:UK'> не слід застосовувати цей препарат.<o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'text-align:justify'><u><span lang=3DUK
style=3D'font-size:12.0pt;mso-ansi-language:UK'>Прийом лікарського засобу Б=
іоарон
СИСТЕМ після вакцинації<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>З огляду на механізм дії лікарського засобу йо=
го
не слід застосовувати відразу після профілактичних щеплень, необхідно
дотримуватися перерви не менше 2 тижнів.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>За умови дотримання вищезазначеного застережен=
ня
препарат можна застосовувати незалежно від графіка вакцинації.<o:p></o:p></=
span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><u><span lang=3DUK
style=3D'font-size:12.0pt;mso-ansi-language:UK'>Прийом препарату під час
хіміотерапії онкологічних захворювань або після завершення лікування<o:p></=
o:p></span></u></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Лікарський засіб не рекомендується застосовува=
ти у
період хіміотерапії онкологічних захворювань. Відсутні протипоказання щодо
застосування цього препарату після закінчення терапії.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><u><span lang=3DUK
style=3D'font-size:12.0pt;mso-ansi-language:UK'>Діти <o:p></o:p></span></u>=
</p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Через відсутність даних цей лікарський засіб не
слід застосовувати дітям віком до 3 років.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Біоарон СИСТЕМ містить 6,6 мг натрію бензоату в
одній дозі (5 мл), що відповідає 0,13 г на 100&nbsp;мл сиропу.<o:p></o:p></=
span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>Зас=
тосування
у період вагітності або годування груддю.<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Через відсутність даних про прийом екстракту а=
лое
вагітними та жінками, які годують груддю, не рекомендується застосовувати
Біоарон СИСТЕМ цим групам пацієнтів. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Дослідження на тваринах не показали жодних
негативних наслідків застосування </span><i style=3D'mso-bidi-font-style:no=
rmal'><span
lang=3DUK style=3D'font-size:12.0pt;mso-fareast-font-family:Calibri;mso-ans=
i-language:
UK'>Aloes arborescens </span></i><span lang=3DUK style=3D'font-size:12.0pt;
mso-ansi-language:UK'>для розвитку плода та перебігу вагітності. Токсичний
вплив на функції репродуктивної системи не був продемонстрований.</span><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
mso-fareast-font-family:Calibri;mso-ansi-language:UK'><o:p></o:p></span></i=
></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Вплив Біоарон СИСТЕМ на плідність не встановле=
ний.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'font-size:12.0pt;mso-ansi-language:UK'>Здатність впливати на швидк=
ість
реакції при керуванні автотранспортом або іншими механізмами.<o:p></o:p></s=
pan></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>З огляду на склад препарату цей лікарський зас=
іб
не впливає на здатність керувати транспортними засобами або працювати з інш=
ими
механізмами.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;mso-ansi-language:UK'>Спосіб застосування та дози. <o:p></o:p></span=
></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Застосовувати перорально.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>При
інфекціях верхніх дихальних шляхів: <o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>приймати перед їдою протягом 14 днів:<o:p></o:=
p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>- дорослим, підліткам та дітям віком від 7 рок=
ів –
по 5 мл 3 рази на день,<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>- дітям віком від 3 до 6 років – по 5 мл 2 раз=
и на
день.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>З м=
етою
профілактики:</span></i><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DUK
style=3D'font-size:12.0pt;mso-ansi-language:UK'> <o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>у неінфекційний період приймати препарат перед
їдою протягом 14 днів:<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>- дорослим, підліткам та дітям віком від 7 рок=
ів –
по 5 мл 3 рази на день, <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>- дітям віком від 3 до 6 років – по 5 мл 2 раз=
и на
день.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Лікування слід повторити після 14-денної перер=
ви.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>При
відсутності апетиту: <o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>приймати 5 мл препарату один раз на день за 15
хвилин до основного прийому їжі.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Тривалість лікування<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><u><span lang=3DUK
style=3D'font-size:12.0pt;mso-ansi-language:UK'>При інфекціях верхніх дихал=
ьних
шляхів</span></u><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-languag=
e:UK'>
лікарський засіб слід застосовувати протягом 14 днів. Якщо поліпшення не сп=
остерігається
після 7 днів лікування або якщо симптоми загострюються, пацієнт повинен
проконсультуватися з лікарем.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><u><span lang=3DUK
style=3D'font-size:12.0pt;mso-ansi-language:UK'>З метою профілактики<o:p></=
o:p></span></u></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Препарат слід застосовувати циклами з перервою=
 не
менше 14 днів між циклами (14 днів лікування / 14 днів перерва у застосуван=
ні).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><u><span lang=3DUK
style=3D'font-size:12.0pt;mso-ansi-language:UK'>При відсутності апетиту<o:p=
></o:p></span></u></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Препарат приймають протягом 14 днів. Якщо
поліпшення не спостерігається після 7 днів лікування або якщо симптоми
загострюються, пацієнт повинен проконсультуватися з лікарем. Застосування п=
репарату
можна повторити після 14-денної перерви. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;mso-ansi-language:UK'>Діти<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Безпека та ефективність застосування препарату=
 дітям
віком до 3 років не встановлені.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;mso-ansi-language:UK'>Передозування.</span></i></b><i style=3D'mso-b=
idi-font-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'><o:=
p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK;mso-bidi-font-weight:bold'>За результатами
фармаконагляду не було отримано повідомлень про побічні ефекти після
передозування препаратом Біоарон СИСТЕМ, про виникнення або посилення побіч=
них
ефектів під час або після лікування та в результаті передозування. Повідомл=
ень
про отруєння через передозування аскорбіновою кислотою не надходило. З огля=
ду
на зареєстровані побічні ефекти можна передбачити легкі диспептичні розлади
після передозування препарату.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><i style=3D'm=
so-bidi-font-style:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>Поб=
ічні
реакції.</span></i></b><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DUK
style=3D'font-size:12.0pt;mso-ansi-language:UK'><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Передбачається, що кислота аскорбінова при
застосуванні в терапевтичних дозах не викликає побічних ефектів. На основі
проведених клінічних випробувань можна стверджувати, що Біоарон СИСТЕМ добре
переноситься і не викликає серйозних небажаний наслідків.<o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Побічні реакції при застосуванні лікарського з=
асобу
Біоарон СИСТЕМ, що виникають:<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>- нечасто (&#8805; 1/1000 до &lt;&nbsp;1/100) –
алергічна реакція,<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>- рідко (&#8805; 1/10000 до &lt;&nbsp;1/1000) –
шлункові/диспептичні симптоми.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'><o:=
p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>Тер=
мін
придатності. </span></b><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-=
language:
UK;mso-bidi-font-weight:bold'>3 роки. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Не застосовувати лікарський засіб після закінч=
ення
терміну придатності, зазначеного на упаковці.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'><o:=
p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>Умо=
ви
зберігання.</span></b><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-la=
nguage:
UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Зберігати в оригінальній упаковці при температ=
урі
не вище 25 °С. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Зберігати в недоступному для дітей місці.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>Упа=
ковка. </span></b><span
lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'><o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Флакони по 100 мл. По одному флакону з мірною
склянкою в картонній коробці.<b><o:p></o:p></b></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>Кат=
егорія
відпуску.</span></b><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-lang=
uage:
UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Без рецепта.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
UK
style=3D'font-size:12.0pt;mso-ansi-language:UK'>Виробник. <o:p></o:p></span=
></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Фітофарм Кленка С.А.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p style=3D'margin:0cm;margin-bottom:.0001pt;text-align:justify'><b><span
lang=3DUK style=3D'mso-ansi-language:UK'>Місцезнаходження виробника та адре=
са місця
провадження його діяльності.</span></b><span lang=3DUK style=3D'mso-ansi-la=
nguage:
UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Кленка 1, <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>63-040 Нове М</span><span style=3D'font-size:1=
2.0pt'>’</span><span
lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'>ясто над Вартою, =
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
font-size:
12.0pt;mso-ansi-language:UK'>Польща.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;mso-ansi-language:UK'><o:=
p>&nbsp;</o:p></span></b></p>

</div>

</body>

</html>

------=_NextPart_01D8F861.E5FBF300
Content-Location: file:///C:/6811EA75/UA06870101_B925.files/preview.wmf
Content-Transfer-Encoding: base64
Content-Type: image/x-wmf
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==

------=_NextPart_01D8F861.E5FBF300
Content-Location: file:///C:/6811EA75/UA06870101_B925.files/item0001.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<b:Sources SelectedStyle=3D"\APASixthEditionOfficeOnline.xsl" StyleName=3D"=
APA" Version=3D"6" xmlns:b=3D"http://schemas.openxmlformats.org/officeDocum=
ent/2006/bibliography" xmlns=3D"http://schemas.openxmlformats.org/officeDoc=
ument/2006/bibliography"></b:Sources>

------=_NextPart_01D8F861.E5FBF300
Content-Location: file:///C:/6811EA75/UA06870101_B925.files/props002.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<ds:datastoreItem ds:itemID=3D"{DB39976B-AD0E-43A9-A691-7E1791CDDCD5}" xmln=
s:ds=3D"http://schemas.openxmlformats.org/officeDocument/2006/customXml"><d=
s:schemaRefs><ds:schemaRef ds:uri=3D"http://schemas.openxmlformats.org/offi=
ceDocument/2006/bibliography"/></ds:schemaRefs></ds:datastoreItem>
------=_NextPart_01D8F861.E5FBF300
Content-Location: file:///C:/6811EA75/UA06870101_B925.files/themedata.thmx
Content-Transfer-Encoding: base64
Content-Type: application/vnd.ms-officetheme

UEsDBBQABgAIAAAAIQDp3g+//wAAABwCAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKyRy07DMBBF
90j8g+UtSpyyQAgl6YLHjseifMDImSQWydiyp1X790zSVEKoIBZsLNkz954743K9Hwe1w5icp0qv
8kIrJOsbR12l3zdP2a1WiYEaGDxhpQ+Y9Lq+vCg3h4BJiZpSpXvmcGdMsj2OkHIfkKTS+jgCyzV2
JoD9gA7NdVHcGOuJkTjjyUPX5QO2sB1YPe7l+Zgk4pC0uj82TqxKQwiDs8CS1Oyo+UbJFkIuyrkn
9S6kK4mhzVnCVPkZsOheZTXRNajeIPILjBLDsAyJX89nIBkt5r87nons29ZZbLzdjrKOfDZezE7B
/xRg9T/oE9PMf1t/AgAA//8DAFBLAwQUAAYACAAAACEApdan58AAAAA2AQAACwAAAF9yZWxzLy5y
ZWxzhI/PasMwDIfvhb2D0X1R0sMYJXYvpZBDL6N9AOEof2giG9sb69tPxwYKuwiEpO/3qT3+rov5
4ZTnIBaaqgbD4kM/y2jhdj2/f4LJhaSnJQhbeHCGo3vbtV+8UNGjPM0xG6VItjCVEg+I2U+8Uq5C
ZNHJENJKRds0YiR/p5FxX9cfmJ4Z4DZM0/UWUtc3YK6PqMn/s8MwzJ5PwX+vLOVFBG43lExp5GKh
qC/jU72QqGWq1B7Qtbj51v0BAAD//wMAUEsDBBQABgAIAAAAIQBreZYWgwAAAIoAAAAcAAAAdGhl
bWUvdGhlbWUvdGhlbWVNYW5hZ2VyLnhtbAzMTQrDIBBA4X2hd5DZN2O7KEVissuuu/YAQ5waQceg
0p/b1+XjgzfO3xTVm0sNWSycBw2KZc0uiLfwfCynG6jaSBzFLGzhxxXm6XgYybSNE99JyHNRfSPV
kIWttd0g1rUr1SHvLN1euSRqPYtHV+jT9yniResrJgoCOP0BAAD//wMAUEsDBBQABgAIAAAAIQCl
Xn0txwYAANcbAAAWAAAAdGhlbWUvdGhlbWUvdGhlbWUxLnhtbOxZz24bRRi/I/EOo723sRMnjaM6
VezYDbRpo9gt6nG8Hu9OM7uzmhkn9a1Kj0ggREEcqARcOCAgUou4tO/gPkOgCIrUV+Cbmd31Tryh
SRtBBc0h3p39ff//zDe7Fy/diRjaJUJSHje86vmKh0js8wGNg4Z3o9c5t+whqXA8wIzHpOGNifQu
rb77zkW8okISEQT0sVzBDS9UKlmZm5M+LGN5nickhmdDLiKs4FYEcwOB94BvxObmK5WluQjT2EMx
joDt5JvJT5PHkwN0fTikPvFWM/5tBkJiJfWCz0RXcycZ0ddP9ycHkyeTR5ODp3fh+gn8fmxoBztV
TSHHssUE2sWs4YHoAd/rkTvKQwxLBQ8aXsX8eXOrF+fwSkrE1DG0BbqO+UvpUoLBzryRKYJ+LrTa
qdUvrOf8DYCpWVy73W61qzk/A8C+D5ZbXYo8a53lajPjWQDZy1nercpipebiC/wXZnSuN5vNxXqq
i2VqQPayNoNfrizV1uYdvAFZ/OIMvtZca7WWHLwBWfzSDL5zob5Uc/EGFDIa78ygdUA7nZR7Dhly
tlEKXwb4ciWFT1GQDXm2aRFDHquT5l6Eb3PRAQJNyLCiMVLjhAyxD4newlFfUKwF4hWCC0/ski9n
lrRsJH1BE9Xw3k8wFM2U34vH3794/BAd7j863P/58N69w/0fLSOHagPHQZHq+bef/PngLvrj4VfP
739WjpdF/K8/fPjLk0/LgVBOU3WefX7w26ODZ1989Pt390vgawL3i/AejYhE18ge2uYRGGa84mpO
+uJ0FL0Q0yLFWhxIHGMtpYR/W4UO+toYszQ6jh5N4nrwpoB2Uga8PLrtKNwNxUjREslXwsgBbnLO
mlyUeuGKllVwc28UB+XCxaiI28Z4t0x2C8dOfNujBPpqlpaO4a2QOGpuMRwrHJCYKKSf8R1CSqy7
Ranj103qCy75UKFbFDUxLXVJj/adbJoSbdAI4jIusxni7fhm8yZqclZm9TrZdZFQFZiVKN8jzHHj
ZTxSOCpj2cMRKzr8KlZhmZLdsfCLuLZUEOmAMI7aAyJlGc11AfYWgn4FQwcrDfsmG0cuUii6U8bz
Kua8iFznO60QR0kZtkvjsIh9T+5AimK0xVUZfJO7FaLvIQ44PjbcNylxwv3ybnCDBo5K0wTRT0ai
JJaXCXfytztmQ0xMq4Em7/TqiMZ/17gZhc5tJZxd44ZW+ezLByV6v6ktew12r7Ka2TjSqI/DHW3P
LS4G9M3vzut4FG8RKIjZLeptc37bnL3/fHM+rp7PviVPuzA0aD2L2MHbjOHRiafwIWWsq8aMXJVm
EJewFw06sKj5mEMqyU9pSQiXurJBoIMLBDY0SHD1AVVhN8QJDPFVTzMJZMo6kCjhEg6TZrmUt8bD
QUDZo+iiPqTYTiKx2uQDu7ygl7OzSM7GaBWYA3AmaEEzOKmwhQspU7DtVYRVtVInllY1qpkm6UjL
TdYuNod4cHluGizm3oQhB8FoBF5egtcEWjQcfjAjA+13G6MsLCYKZxkiGeIBSWOk7Z6NUdUEKcuV
GUO0HTYZ9MHyJV4rSKtrtq8h7SRBKoqrHSMui97rRCnL4GmUgNvRcmRxsThZjPYaXn1xftFDPk4a
3hDOzXAZJRB1qedKzAJ4P+UrYdP+pcVsqnwazXpmmFsEVXg1Yv0+Y7DTBxIh1TqWoU0N8yhNARZr
SVb/+UVw61kZUNKNTqbFwjIkw7+mBfjRDS0ZDomvisEurGjf2du0lfKRIqIbDvZQn43ENobw61QF
ewZUwusP0xH0Dby70942j9zmnBZd8Y2Zwdl1zJIQp+1Wl2hWyRZuGlKug7krqAe2lepujDu9Kabk
z8iUYhr/z0zR+wm8jVgY6Aj48DZZYKQrpeFxoUIOXSgJqd8RMEiY3gHZAu9/4TEkFbzTNr+C7Opf
W3OWhylrOFSqbRogQWE/UqEgZAvaksm+lzCrpnuXZclSRiajCurKxKrdJ7uE9XQPXNJ7u4dCSHXT
TdI2YHBH88+9TyuoH+ghp1hvTifL915bA//05GOLGYxy+7AZaDL/5yrm48F0V7X0hjzbe4uG6AfT
MauWVQUIK2wF9bTsX1GFU261tmPNWDy/mCkHUZy1GBbzgSiBd0pI/4P9jwqf2a8jekPt8W3orQg+
bmhmkDaQ1efs4IF0g7SLfRic7KJNJs3KujYdnbTXss36jCfdXO4RZ2vNThLvUzo7H85ccU4tnqWz
Uw87vrZrx7oaInu0RGFpmB1sTGDMl7Xily/evw2BXodvCCOmpEkm+I4lMMzQXVMHUPxWoiFd/QsA
AP//AwBQSwMEFAAGAAgAAAAhAA3RkJ+2AAAAGwEAACcAAAB0aGVtZS90aGVtZS9fcmVscy90aGVt
ZU1hbmFnZXIueG1sLnJlbHOEj00KwjAUhPeCdwhvb9O6EJEm3YjQrdQDhOQ1DTY/JFHs7Q2uLAgu
h2G+mWm7l53JE2My3jFoqhoIOumVcZrBbbjsjkBSFk6J2TtksGCCjm837RVnkUsoTSYkUiguMZhy
DidKk5zQilT5gK44o49W5CKjpkHIu9BI93V9oPGbAXzFJL1iEHvVABmWUJr/s/04GolnLx8WXf5R
QXPZhQUoosbM4CObqkwEylu6usTfAAAA//8DAFBLAQItABQABgAIAAAAIQDp3g+//wAAABwCAAAT
AAAAAAAAAAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAKXWp+fA
AAAANgEAAAsAAAAAAAAAAAAAAAAAMAEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAGt5lhaD
AAAAigAAABwAAAAAAAAAAAAAAAAAGQIAAHRoZW1lL3RoZW1lL3RoZW1lTWFuYWdlci54bWxQSwEC
LQAUAAYACAAAACEApV59LccGAADXGwAAFgAAAAAAAAAAAAAAAADWAgAAdGhlbWUvdGhlbWUvdGhl
bWUxLnhtbFBLAQItABQABgAIAAAAIQAN0ZCftgAAABsBAAAnAAAAAAAAAAAAAAAAANEJAAB0aGVt
ZS90aGVtZS9fcmVscy90aGVtZU1hbmFnZXIueG1sLnJlbHNQSwUGAAAAAAUABQBdAQAAzAoAAAAA

------=_NextPart_01D8F861.E5FBF300
Content-Location: file:///C:/6811EA75/UA06870101_B925.files/colorschememapping.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"yes"?>
<a:clrMap xmlns:a=3D"http://schemas.openxmlformats.org/drawingml/2006/main"=
 bg1=3D"lt1" tx1=3D"dk1" bg2=3D"lt2" tx2=3D"dk2" accent1=3D"accent1" accent=
2=3D"accent2" accent3=3D"accent3" accent4=3D"accent4" accent5=3D"accent5" a=
ccent6=3D"accent6" hlink=3D"hlink" folHlink=3D"folHlink"/>
------=_NextPart_01D8F861.E5FBF300
Content-Location: file:///C:/6811EA75/UA06870101_B925.files/header.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1251"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns:st1=3D"urn:schemas-microsoft-com:office:smarttags"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
1">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 14">
<meta name=3DOriginator content=3D"Microsoft Word 14">
<link id=3DMain-File rel=3DMain-File href=3D"../UA06870101_B925.htm">
<![if IE]>
<base href=3D"file:///C:\6811EA75\UA06870101_B925.files\header.htm"
id=3D"webarch_temp_base_tag">
<![endif]><o:SmartTagType
 namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"metricconverter"/>
</head>

<body lang=3DRU>

<div style=3D'mso-element:footnote-separator' id=3Dfs>

<p class=3DMsoNormal><span style=3D'mso-special-character:footnote-separato=
r'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></p>

</div>

<div style=3D'mso-element:footnote-continuation-separator' id=3Dfcs>

<p class=3DMsoNormal><span style=3D'mso-special-character:footnote-continua=
tion-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></p>

</div>

<div style=3D'mso-element:endnote-separator' id=3Des>

<p class=3DMsoNormal><span style=3D'mso-special-character:footnote-separato=
r'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></p>

</div>

<div style=3D'mso-element:endnote-continuation-separator' id=3Decs>

<p class=3DMsoNormal><span style=3D'mso-special-character:footnote-continua=
tion-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></p>

</div>

<div style=3D'mso-element:footer' id=3Def1>

<div style=3D'mso-element:frame;mso-element-wrap:around;mso-element-anchor-=
vertical:
paragraph;mso-element-anchor-horizontal:margin;mso-element-left:right;
mso-element-top:.05pt;mso-height-rule:exactly'>

<table cellspacing=3D0 cellpadding=3D0 hspace=3D0 vspace=3D0 align=3Dright>
 <tr>
  <td valign=3Dtop align=3Dleft style=3D'padding-top:0cm;padding-right:0cm;
  padding-bottom:0cm;padding-left:0cm'>
  <p class=3DMsoFooter style=3D'mso-element:frame;mso-element-wrap:around;
  mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:margi=
n;
  mso-element-left:right;mso-element-top:.05pt;mso-height-rule:exactly'><!-=
-[if supportFields]><span
  class=3DMsoPageNumber><span style=3D'mso-element:field-begin'></span>PAGE=
<span
  style=3D'mso-spacerun:yes'>  </span></span><![endif]--><!--[if supportFie=
lds]><span
  class=3DMsoPageNumber><span style=3D'mso-element:field-end'></span></span=
><![endif]--><span
  class=3DMsoPageNumber><o:p></o:p></span></p>
  </td>
 </tr>
</table>

</div>

<p class=3DMsoFooter style=3D'margin-right:18.0pt'><o:p>&nbsp;</o:p></p>

</div>

<div style=3D'mso-element:footer' id=3Df1>

<div style=3D'mso-element:frame;mso-element-wrap:around;mso-element-anchor-=
vertical:
paragraph;mso-element-anchor-horizontal:margin;mso-element-left:right;
mso-element-top:.05pt;mso-height-rule:exactly'>

<table cellspacing=3D0 cellpadding=3D0 hspace=3D0 vspace=3D0 align=3Dright>
 <tr>
  <td valign=3Dtop align=3Dleft style=3D'padding-top:0cm;padding-right:0cm;
  padding-bottom:0cm;padding-left:0cm'>
  <p class=3DMsoFooter style=3D'mso-element:frame;mso-element-wrap:around;
  mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:margi=
n;
  mso-element-left:right;mso-element-top:.05pt;mso-height-rule:exactly'><sp=
an
  class=3DMsoPageNumber><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
</table>

</div>

<p class=3DMsoFooter style=3D'margin-right:18.0pt'><o:p>&nbsp;</o:p></p>

</div>

</body>

</html>

------=_NextPart_01D8F861.E5FBF300
Content-Location: file:///C:/6811EA75/UA06870101_B925.files/filelist.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml; charset="utf-8"

<xml xmlns:o=3D"urn:schemas-microsoft-com:office:office">
 <o:MainFile HRef=3D"../UA06870101_B925.htm"/>
 <o:File HRef=3D"preview.wmf"/>
 <o:File HRef=3D"item0001.xml"/>
 <o:File HRef=3D"props002.xml"/>
 <o:File HRef=3D"themedata.thmx"/>
 <o:File HRef=3D"colorschememapping.xml"/>
 <o:File HRef=3D"header.htm"/>
 <o:File HRef=3D"filelist.xml"/>
</xml>
------=_NextPart_01D8F861.E5FBF300--
